GILD Archives - Page 2 of 29

1 minute read

Events
News

Gilead And Arcus Announced Etrumadenant Plus Zimberelimab, FOLFOX, And Bevacizumab Reduce Death Risk By 63% And Disease Progression by 73% vs Regorafenib In Phase 1b/2 Trial For Third-Line Metastatic Colorectal Cancer

June 2, 10:36 AM

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine

GILD

2 minute read

Gilead’s Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer

By Vandana Singh

May 31, 9:27 AM

Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but showed numerical improvements favoring Trodelvy.

GILD

1 minute read

Gilead Sciences To Present EVOKE-01 Study Results In Metastatic NSCLC At An Oral Session At ASCO 2024

By Benzinga Newsdesk

May 31, 8:16 AM

– Simultaneously Published by the Journal of Clinical Oncology –Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract

GILD

2 minute read

Gilead’s Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch

By Vandana Singh

May 20, 9:36 AM

Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus.

GILD

2 minute read

Market Whales and Their Recent Bets on GILD Options

By Benzinga Insights

May 15, 1:46 PM

Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead…

GILD

2 minute read

Decoding Gilead Sciences’s Options Activity: What’s the Big Picture?

By Benzinga Insights

May 10, 1:52 PM

Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead…

GILD

2 minute read

Gilead Sciences Unusual Options Activity For May 06

By Benzinga Insights

May 6, 3:15 PM

Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead…

GILD

2 minute read

How Is The Market Feeling About Gilead Sciences?

By Benzinga Insights

May 6, 9:15 AM

Gilead Sciences’s (NYSE:GILD) short percent of float has risen 4.62% since its last report. The company recently reported…

GILD

3 minute read

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week

By Shanthi Rexaline

Yesterday, 1:51 AM

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.

AAL

3 minute read

Gilead Sciences Unusual Options Activity

By Benzinga Insights

April 26, 3:15 PM

Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ:GILD), and it’s something market players shouldn’t ignore.…

GILD

Feed Symbols: GILD